Drug Profile
Research programme: kidney disease therapeutics - Bayer/Evotec SE
Alternative Names: BAYxxxLatest Information Update: 20 Jan 2022
Price :
$50
*
At a glance
- Originator Bayer; Evotec AG
- Developer Bayer; Evotec SE
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Endometriosis; Kidney disorders
Most Recent Events
- 20 Jan 2022 Preclinical trials in Endometriosis in Germany (unspecified route) (Evotec pipeline, January 2022)
- 28 Oct 2020 No recent reports of development identified for research development in Kidney-disorders in Germany
- 28 Oct 2020 No recent reports of development identified for research development in Kidney-disorders in USA